


6p 1654
Bhu/B



98204.00019

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Robert H. Zimmer

Serial No.: 10/050,903

Filed: January 16, 2002

)
)
) Examiner: Teller, Roy R.

)
) Group Art Unit: 1654

)
) Confirmation No. 5841

For: PROCESS TO IMPROVE OR PERMIT THE ORAL ABSORPTION OF
POLYPEPTIDE DRUG SUBSTANCES AND OTHER POORLY ORALLY
ABSORBED DRUGS WHILE MAINTAINING THEIR
PHARMACOLOGICAL EFFECTS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the documents listed on the attached form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with examination of the above-identified patent application.

This Supplemental Information Disclosure Statement is being filed after the mailing date of a Notice of Allowance in connection with the present application. (See 37 CFR § 1.98(d)).

Applicant hereby requests that the documents submitted herewith be placed of record in the file for the present application pursuant to 37 CFR § 1.98(i).\

The filing of this Supplemental Information Disclosure Statement shall not be construed to be a representation that a search has been conducted, nor shall it be construed as an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

Respectfully submitted,

Date: October 18, 2004




Basam E. Nabulsi
Reg. No. 31,645
Attorney for Applicants

McCarter & English, LLP
Four Stamford Plaza
107 Elm Street
Stamford, CT 06902
(203) 965-0601

I hereby certify that the enclosed Supplemental Information Disclosure Statement along with a PTO-1449 Form and cited references is being deposited with the United States Postal Service as first class mail, postage prepaid, addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on October 18, 2004.

Dated: October 18, 2004


Joan Simmons

HARTFORD: 625066.01

Form PTO-1449 (modified 2/91)	U.S. DEPT OF COMMERCE Patent and Trademark Office	Attorney Docket Number: 98204.00019	Serial No.: 10/050,903
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Applicants:	
		Robert H. Zimmer	
		Filing date: 1/16/02	Group Art Unit: 1654



U.S. PATENT DOCUMENTS

Examiner Initial	Patent number	Date	Inventor	Class	Sub class	Filing date if appropriate
	4,239,754	12/16/1980	Sache et al.			
	4,339,534	7/13/1982	Johansen et al.			
	4,396,606	8/2/1983	Goldstein			
	4,694,006	9/15/1987	Bundgaard et al.			
	4,925,673	5/15/1990	Steiner et al.			
	5,212,158	5/18/1993	Vandai			

FOREIGN PATENT DOCUMENTS

Document number	Date	Country	Class	Sub class	Translation Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Ahlers, et al., Enhanced Immunogenicity of HIV-1 Vaccine Construct By Modification of the Native Peptide Sequence, Proc. Natl. Acad. Sci. USA, Vol. 94, pp. 10856-10861, September 1997.
	Greenstein, et al., A Universal T Cell Epitope-Containing Peptide From Hepatitis B Surface Antigen Can Enhance Antibody Specific For HIV gp120, Journal of Immunology, Vol. 148, pp. 3970-3977, No. 12, June 1992.
	Belyakov, et al., The Importance of Local Mucosal HIV-Specific CD8 ⁺ Cytotoxic T Lymphocytes For Resistance to Mucosal Viral Transmission in Mice and Enhancement of Resistance by Local Administration of IL-12, The Journal of Clinical Investigation, Vol. 102(12); pp. 2072-2081, December 1998.
	Belyakov, et al., Mucosal Immunization With HIV-1 Peptide Vaccine Induces Mucosal and Systemic Cytotoxic T Lymphocytes and Protective Immunity In Mice Against Intrarectal Recombinant HIV_Vaccinia Challenge, Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 1709-1714, February 1998.
	Patel, et al., Oral Administration of Insulin By Encapsulation Within Liposomes, North-Holland Publishing Company, Volume 62, No. 1, pp. 60-63, February 1976.
	Hashimoto, et al., ACTH Release in Pituitary Cell Cultures, Effect of Neurogenic Peptides and Neurotransmitter Substances Corticotropin Releasing Factor (CRF), Endocrinol. Japan, Vol. 26 (1), pp. 103-109, February 1979.

Examiner:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	